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Abstract 
Background: In April 2010, revised Prevention of Mother-to-Child Transmission guidelines were 
implemented in South Africa, advising fast-tracked lifelong highly active antiretroviral therapy 
(HAART) initiation at a higher CD4 count (≤350 cells per microliter). This study describes the 
impact of these changes on the management of pregnant women who initiated HAART at 
Tygerberg Hospital, Cape Town. 
Methods: We conducted a retrospective review of all women who initiated HAART in 
pregnancy at the Tygerberg Hospital between January 2008 and December 2010. Year cohorts 
were compared. 
Results: Two hundred and fifty HIV-infected women were included in the study and stratified by 
HAART initiation year: 2008:N = 82, 2009:N = 71, 2010:N = 97. There were no differences 
between the groups in age or parity. Median booking CD4 count was 155 cells per microliter 
[interquartile range (IQR) 107–187], 157 cells per microliter (IQR 104–206) and 208 cells per 
microliter (IQR 138–270), respectively (P < 0.001). Median gestation at HAART initiation was 
31 weeks (IQR 27–35), 30 weeks (IQR 26–34), and 25 weeks (IQR 21–31; P < 0.001). HIV 
transmission rates were 3/65 (4.6%), 4/57 (7.0%), and 0/90 (0.0%; P = 0.021). Women <8 weeks 
on HAART before delivery were more likely to transmit than women ≥8 weeks [odds ratio 9.69; 
95% confidence interval 1.66 to 56.58; P = 0.017]. Ninety-four (37.6%) women were lost to 
follow-up, 18.4% within 28 days of delivery. 
Conclusions: The positive impact of the new Prevention of Mother-to-Child Transmission 
program is evident. A longer duration of HAART before delivery was associated with less 
transmission. However, the lost to follow-up rates remain concerning. Further research is needed 
to better understand the reasons for nonadherence and mechanisms to improve support for these 
women. 
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INTRODUCTION 
With an estimated 5.6 million (5.4 million–5.8 million) HIV-infected people, South Africa 
continues to have the world's largest HIV epidemic.
1
 In 2010, the overall HIV prevalence among 
pregnant women attending antenatal clinics in South Africa was 30.2%. It is estimated that in 
2010, there were 260,280 women in need of Prevention of Mother-to-Child Transmission 
(PMTCT) services, and 54,000 new infections occurred among children under 14 years of age. In 
the Cape Town Metro, the HIV prevalence among pregnant women attending antenatal services 
was 20.2% [95% confidence interval (CI) 15.7 to 25.6].
2
 This figure is comparable with the HIV 
prevalence among women delivering at Tygerberg Hospital, which was 19% in 2010 (Tygerberg 
Delivery PMTCT Register). 
Since April 2003, several PMTCT interventions have been implemented at all public sector 
antenatal service facilities in the Western Cape, South Africa, ensuring all pregnant women with 
a low CD4 count eligible for lifelong highly active antiretroviral therapy (HAART). In the 2008 
Western Cape PMTCT guidelines HAART was advised in cases with CD4 counts <250 cells per 
microliter or World Health Organization (WHO) Stage 4. Cases with higher CD4 counts were, 
according to National PMTCT guidelines, provided with PMTCT prophylaxis, consisting of 
Zidovudine monotherapy from 28 weeks gestation until delivery, adding single dose Nevirapine 
(NVP) at the time of delivery. HIV-exposed infants received single dose NVP and Zidovudine 
monotherapy for 7 or 28 days depending on the duration of maternal PMTCT prophylaxis or 
HAART.
3
 In April 2010, revised PMTCT guidelines were implemented, proposing fast-tracked 
HAART initiation within 2 weeks of diagnosis for all women with CD4 counts ≤350 cells per 
microliter or WHO stage 3 or 4 disease. Dual therapy is advised at earlier gestation, from 14 
weeks onwards. HIV-exposed infants receive a minimum of 6 weeks of NVP.
4
 
In the developed world, HIV transmission rates can be minimized to 0%–2.9% when HAART is 
initiated early in pregnancy.
5,6
 Limited cohort data are available that report the performance of 
the ART services in the public sector in South Africa. The national PMTCT evaluation survey 
reported an overall MTCT rate of 3.9% (1.9–5.8) in the Western Cape in 2010.7 A recent study 
from a community-based clinic in Cape Town described a rate of 5.1% in women initiated on 
HAART before delivery.
8
 This study describes the cohort of pregnant women who initiated 
HAART at Tygerberg Infectious Diseases (ID) Clinic and describes the annual MTCT outcomes 
to evaluate the impact of the new guidelines. 
METHODS 
The Tygerberg ID Clinic is based in Tygerberg Academic Hospital and provides tertiary level 
infectious diseases specialist care to half of the Western Cape Province and primary level ART 
care to the population living in Tygerberg subdistrict. Pregnant women requiring HAART are 
referred from the Tygerberg High Risk Antenatal Care Clinic (ANC) and several community-
based ANC clinics in the subdistrict that have no ART facilities. We conducted a retrospective 
cohort study and reviewed all women who initiated HAART in pregnancy at Tygerberg ID 
Clinic between January 2008 and December 2010. Clinical data of all patients referred to 
Tygerberg are routinely collected on a prospectively maintained clinic database in the Tygerberg 
ID Clinic, supported by funding from the President's Emergency Plan for AIDS Relief. 
Indicators extracted for the study were baseline CD4 count, gestation at booking, first ART 
clinic visit, HAART initiation and delivery, duration of HAART before delivery and before lost 
to follow-up (LTFU) and concurrent comorbidities including WHO clinical HIV staging. 
Neonatal outcomes were verified with the Tygerberg Delivery PMTCT Register and the regional 
laboratory polymerase chain reaction (PCR) test database. 
Data were captured on a customized MS Excel spread sheet and analyzed using Statistica version 
10 (Statsoft, Tulsa, OK). Descriptive statistics were performed per year cohort, using medians 
and standard deviations to include their measure of spread. Mann–Whitney U tests were used to 
compare medians. Contingency tables were constructed and Fisher exact, and χ2 tests were done 
to determine significant differences between proportions. Two-tailed P < 0.05 were considered 
statistically significant. Odds ratios (ORs) were calculated to determine the risk of vertical 
transmission. The study was approved by the University of Stellenbosch Health Research Ethics 
Committee (N11/04/132). 
RESULTS 
During the 3-year study period, 250 pregnant women initiated lifelong HAART at Tygerberg ID 
Clinic. The majority of this cohort (69%) presented with uncomplicated WHO stage I HIV 
infection. A total of 256 live births were reported, including 12 pairs of twins. The study group 
was stratified per initiation year: 2008 N = 82 patients, 2009 N = 71 patients, 2010 N = 97 
patients. Patient demographics are presented in Table 1. Baseline characteristics of the 3 groups 
were comparable, with no statistical difference in median age, parity, and gestation at delivery. 
Besides an expedited HAART initiation after booking, no other significant differences were 
found comparing the 2009 cohort to the 2008 cohort. Median CD4 count at the first antenatal 
clinic visit was significantly different in 2010 compared with that in 2009 {208 cells per 
microliter [interquartile range (IQR) 138–270] vs. 157 cells per microliter [IQR 104–206], P < 
0.001} and in association with the proportion of patients presenting with WHO stage 3 or 4 
clinical disease was significantly different in 2010 as well (11.3% vs. 23.9%, P = 0.030). Also, 
median gestation at the first antenatal clinic visit [17 weeks (IQR 14–25) vs. 23 weeks (IQR 16–
27), P = 0.026] and median gestation at HAART initiation [25 weeks (IQR 21–31) vs. 30 weeks 
(IQR 26–34), P < 0.001] were significantly different in 2010 compared with that in 2009. The 
percentage of women receiving >8 weeks of HAART before delivery increased significantly 
from 47.8% in 2009 to 73.7% in 2010 (P < 0.001). 
Table 1 Demographics of Study Cohort 
 
 
We compared the first antenatal clinic visit with first visit date at our facility and HAART 
initiation date. The median time between the first antenatal visit and the actual HAART initiation 
did not differ between 2009 and 2010 (P = 0.173). The median time between first clinic 
attendance at our facility and HAART initiation however was significantly different in 2010 
compared with that in 2009 [1.1 weeks (IQR 1.0–2.0) vs. 2.0 weeks (IQR 0.8–3.8), P = 0.030]. 
Neonatal outcomes are presented in Table 2. Out of a total of 256 live births, 212 (82.8%) 
follow-up neonatal HIV PCR results were found. There was a significant improvement in the 
availability of PCR results from 57/75 (76.0%) in 2009 to 90/99 (90.9%) in 2010 (P = 0.016). 
HIV transmission rates per year cohort were 4.6% (n = 3), 7.0% (n = 4), and 0.0% (n = 0), which 
were significantly lower in 2010 compared with 2009 (P = 0.021). The duration of HAART 
before delivery was known in 242 (96.8%) cases, of which 211 had a known PCR result (Table 
3). Women on HAART for <8 weeks before delivery were more likely to transmit than women 
who were on HAART for >8 weeks [OR 9.69 (95% CI 1.66 to 56.58, P = 0.017)]. No significant 
association was found between maternal age, maternal parity, booking CD4 count, WHO 
staging, booking gestation or delivery gestation, and HIV transmission. 
Table 2 Neonatal Outcomes by Year of HAART Initiation
 
Table 3 Neonatal HIV Status by Maternal Characteristics
 
Of 250 women initiated, 99 were LTFU of whom 46 (18.4%) within 28 days of delivery and 94 
(37.6%) within a year of HAART initiation (Table 4). LTFU numbers per initiation year were 26 
(31.7%), 39 (54.9%), and 34 (35.1%), with 46/99 (46.5%) of all LTFU occurring within the first 
8 weeks after HAART initiation. LTFU rates were higher in 2009 compared with those in 2008 
but improved again in 2010. LTFU women who were initiated on 36 weeks of gestation and later 
were significantly more likely to become LTFU within 4 weeks of initiation [7/27 (25.9%), vs. 
23/223 (10.3%), P = 0.028]. 
Table 4 Mothers Lost to Follow-Up by Year of HAART Initiation
 
DISCUSSION 
We describe the characteristics of a cohort of pregnant women who initiated lifelong HAART 
during pregnancy in an urban public ART clinic in the Western Cape, South Africa, over 3 
consecutive years. 
When comparing the 2010 cohort with the 2009 cohort, we found that the median CD4 count at 
the first antenatal visit increased significantly. We also found that the median gestation at first 
antenatal visit and median gestation at HAART initiation had decreased. Not surprisingly, there 
was also a significant increase in the duration of HAART until delivery. This is in line with the 
revision of the national PMTCT protocol in April 2010,
4
 ensuring that more pregnant women are 
eligible for HAART referral by increasing the cutoff CD4 count from 250 to 350 cells per 
microliter and recommending fast-tracked HAART initiation within 2 weeks of diagnosis, from 
14-week gestation. Compared with a study from Cape Town describing a cohort of HIV-infected 
pregnant women from 2005 with a median gestation at HAART initiation of 32 weeks,
9
 our 
cohort showed an earlier gestation at initiation from 31 weeks in 2008 to 25 weeks in 2010. As a 
consequence of this, the percentage of women receiving HAART for >8 weeks before delivery 
increased from 48.1% in 2008 (comparable with the 2005 rate in that study) to 73.7% in 2010. 
Thus, the new guideline has impacted the earlier initiation of therapy at higher CD4 count, an 
important factor in reducing MTCT. 
Gestation at the first antenatal visit, HAART initiation, and delivery has been verified with 
antenatal records where possible. However, only 63% of the study participants booked before 24 
weeks of gestation, and no accurate estimation of gestation by ultrasound can be established 
thereafter. Although booking gestation improved significantly in 2010 with a median of 17 
weeks, still 9.2% of women booked at or after 30 weeks of gestation. Overall booking gestation 
is still late in pregnancy, limiting the window of opportunity for successful HAART initiation 
before delivery. Women should be encouraged to book early in pregnancy. Further research is 
needed to identify factors causing delays in booking. 
The changes in the guideline do not seem to have expedited the referral process for HAART 
initiation. Although improvement was found in the median time between booking and actual 
HAART initiation in 2009, no further improvement was found after the introduction of the 
guideline in 2010, with the median time still >5 weeks. It is therefore clear that fast-tracking 
HAART initiation itself was not responsible for the reduction in MTCT, but rather that earlier 
HAART initiation at a higher CD4 count was the main contributor to this outcome. 
Greater improvements might still be achievable by eliminating delays in the referral process for 
HAART initiation. In 2010, only 4.1% of pregnant women were initiated within the stipulated 
time period of 2 weeks after HIV diagnosis as per PMTCT guideline. This clearly identifies the 
current bottleneck of the referral system and poor integration of services. The median time 
between the first visit and HAART initiation at our facility was significantly shorter in 2010 at a 
median of 1.1 weeks, indicating that most treatment delay occurs during referral to our facility. 
Generally, delay is caused by awaiting laboratory results. Whether on-site rapid CD4 count 
measurement could shorten referral delay for pregnant women should be investigated, as this 
would minimize the time to establish HAART eligibility. Baseline blood could be drawn in the 
ANC facility upon referral, enabling ART clinicians with access to regional laboratory results to 
initiate HAART at the first visit if desired. Referral delay from the ANC facility to the ART 
facility might be caused by limited booking capacity for new referrals at the ART facility and 
requires investigation. Expansion of ART sites in the community with fast-track appointment 
slots for pregnant women is recommended. Integration of services with ANC health workers 
initiating and monitoring HAART is proposed, as this would eliminate the referral process 
entirely. Health policy changes toward universal HAART initiation for all HIV-positive pregnant 
women regardless of CD4 count would both reduce MTCT and simplify the initiation process. 
The HIV transmission rate has decreased significantly with no transmission detected in 2010, 
compared with 7.0% in 2009. In 2010, the vertical HIV transmission rate at Tygerberg ID Clinic 
was comparable with the rates achieved in developed countries, which is an important milestone. 
Further studies are needed to show the impact on maternal health of starting therapy at higher 
CD4 counts. Our study confirmed that a longer duration of HAART in pregnancy was associated 
with decreased HIV transmission. No significant association was found between maternal age, 
maternal parity, booking CD4 count, booking gestation or delivery gestation, and HIV 




The availability of neonatal PCR results had significantly improved in 2010, with only 9.1% of 
PCR results unknown compared to 24% in 2009. Several factors contribute to the unavailability 
of neonatal PCR results, such as early neonatal death, migration, LTFU, errors in personal detail 
registration at the National Health Laboratory Service or Community Health Clinic, and lack of 
feedback systems between ART site and ANC and baby Community Health Clinics. Due to the 
retrospective nature of the study, information and selection bias may have occurred. As a result 
of the high number of LTFU after delivery, a number of baby birth dates and names could not be 
verified. This contributed to 17% of PCR results being unknown, possibly leading to the 
underestimation of transmission rates. 
LTFU rates were unacceptably high at 37.6% within 1 year of initiation, with 18.4% of all LTFU 
occurring within 28 days of delivery date, which is generally within 8 weeks of initiation. 
Women initiating HAART in pregnancy are significantly more likely to become LTFU than are 
nonpregnant women initiating HAART.
10,11
 Interestingly, those women who were more 
established on therapy had a lower risk of LTFU. Several reasons could contribute to the poor 
retention in care around delivery, such as poor maternal health, fast-tracked initiation with too 
little time to come to terms with recent HIV diagnosis, inadequate support with no regular 
contact with health care services related to the pregnancy, poor socioeconomic circumstances 
undermining transport and childcare availability, relocation to family homesteads and multiple 
appointments at postnatal and baby clinics at different locations. Further research is needed to 
better understand how retention in care after delivery can be improved to optimize the healthcare 
status of these vulnerable women and neonates. A possible intervention could be the provision of 
a >1 month prescription at the last predelivery visit to bridge the stressful time around delivery 
and the early postnatal period. 
The LTFU date was recorded as the date of the last clinic or pharmacy attendance without 
recorded transfer out procedures. We may have underestimated the time to actual nonadherence, 
as patients might have adhered until the very end of their provided medication, which is 
generally 28 days. It is also possible that women have self-referred to alternative ART sites to 
obtain further medication, without requesting clinical notes. Likewise, it is uncertain if women 
who have been transferred to other clinics did in fact end up attending these facilities, as no 
feedback system is in place between ART sites. It is however reasonable to assume that most 
women who have not returned for planned follow-up appointments have at least experienced 
some period of treatment interruption, as only the exact amount of needed medication till the 
next follow-up date is dispensed and ART is not readily available in local primary clinics or 
other ART sites without referral letters. Therefore, the magnitude of reported LTFU remains of 
great concern, especially as treatment interruption during breastfeeding might increase the 
transmission risk. Emphasis on retention in care should be promoted by developing efficient 
referral feedback systems between community ANC and baby clinics and strengthening patient 
tracing capacity. 
The Tygerberg ID clinic functions predominantly as a community-based primary level ART care 
facility for those women in need of HAART who live in the local catchment area. However, as 
central referral hospital, the clinic also manages more complicated patients who are referred 
from other antenatal, ART or specialist clinics with specific comorbidity. The impact of these 
referred patients, together with the greater infrastructure at the Tygerberg ID clinic, interact in a 
complex way and limit the extrapolation of the data to other community-based ART clinics in 
South Africa. 
CONCLUSIONS 
Since the institution of the 2010 National PMTCT guideline, women initiated HAART earlier in 
pregnancy, and less MTCT of HIV transmission was evident. Longer duration of HAART before 
delivery was associated with a reduced risk of HIV transmission. 
However, women are still initiating therapy relatively late in pregnancy and retention in care 
remains poor with unacceptable LTFU rates. With earlier access to PMTCT for pregnant women, 
the focus should now shift toward educating women of the benefits of early booking to effect 
immediate referral to ART facilities after HIV diagnosis and ensuring women remain in care in 
the postnatal period. 
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